Piper Sandler lowered the firm’s price target on Abbott (ABT) to $135 from $150 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 results that missed on the topline and came in-line on adjusted EPS, with the majority of the top miss driven by the Nutrition business. While Piper concedes the report was disappointing, it still likes the set-up for FY2026 behind a couple of key product launches, the ongoing momentum in the medtech business, and with the headwinds in the diagnostics business set to largely abate.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $125 from $154 at Bernstein
- Abbott price target lowered to $140 from $155 at Citi
- Abbott price target lowered to $122 from $146 at Wells Fargo
- Buy Rating on Abbott: Near‑Term Nutrition Headwinds Offset by High-Growth MedTech and Attractive 2026 Valuation
- Abbott Laboratories Earnings Call: Devices Offset Nutrition Drag